UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 | |
FORM 12b-25
NOTIFICATION OF LATE FILING | SEC. FILE NUMBER 000-30256 | |||||||
Check One): x Form 10-K and Form 10-KSB Form 20-F Form 11-K Form 10-Q and Form 10-QSB Form N-SAR | CUSIP NUMBER 00756F201 | |||||||
For Period Ended: December 31, 2007 | ||||||||
Transition Report on Form 10-K | ||||||||
Transition Report on Form 20-F | ||||||||
Transition Report on Form 11-K | ||||||||
Transition Report on Form 10-Q | ||||||||
Transition Report on Form N-SAR | ||||||||
For the Transition Period Ended: | ||||||||
Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.
If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:
PART I - REGISTRANT INFORMATION Advanced Plant Pharmaceuticals, Inc. Full Name of Registrant |
not applicable Former Name if Applicable |
43 West 33rd Street Address of Principal Executive Office(Street and Number) New York, New York 10001 City, State and Zip Code |
PART 11 - RULES 12b-25(b) AND (c)
If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate).
x | (a) | The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense; |
x | (b) | The subject annual report, semi-annual report, transition report on Form 10-K, Form 10-KSB, Form 20-F, 11-K or Form N-SAR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report of transition report on Form 10-Q, or portion thereof will be filed on or before the fifth calendar day following the prescribed due date; and |
| (c) | The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable. |
PART III - NARRATIVE
State below in reasonable detail the reasons why Forms 10-K and 10-KSB, 20-F, 11-K, 10-Q and 10-QSB, N-SAR, or the transition report on portion thereof, could not be filed within the prescribed time period.
The Registrant's Form 10-KSB for the year ended December 31, 2007 could not be filed within the prescribed time period because the Registrant has not been able to review certain information and data relating to and necessary for the accurate completion of the Registrant's financial statements. The Registrant anticipates that the Form 10-KSB Annual Report, will be filed on or before the 15th calendar day following the prescribed due date of the Registrant's Form 10-KSB.
PART IV - OTHER INFORMATION
(1) | Name and telephone number of person to contact in regard to this notification | |||
David Lieberman (Name) (212)695-3334 (Area Code and Telephone Number) | ||||
(2) | Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s). | x Yes No | ||
(3) | Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? | Yes x No | ||
If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made | ||||
Advanced Plant Pharmaceuticals, Inc.
(Name of Registrant as Specified in Charter)
has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.
Date: March 31, 2008
By: /s/David Lieberman
David Lieberman, CEO